Multiple Sclerosis (MS

RECENT NEWS
GenEng News  Sep 18  Comment 
Scientists at the University of Virginia (UVA) School of Medicine suggest that lymphatic vessels that clean the brain of harmful material may play a crucial role in the development and progression of multiple sclerosis. The vessels appear to...
FierceBiotech  Sep 17  Comment 
Servier has turned down the chance to license a multiple sclerosis drug from GeNeuro. The decision comes a year after the monoclonal antibody, GNbAC1, failed to beat placebo in a phase 2b trial.
GenEng News  Sep 14  Comment 
Researchers at the Sanford Burnham Prebys Medical Discovery Institute (SBP) say they have identified an astrocyte subpopulation as the dominant active cell type in vivo in a neuroinflammatory disease setting. Their early activation inspired a...
Channel News Asia  Sep 9  Comment 
Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve its drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS).
FiercePharma  Aug 30  Comment 
The multiple sclerosis field has been a hotbed for payers pressing drugmakers to trade formulary spots for discounts. But that’s changed a bit in 2018—and a few companies stand to reap the benefits.
GenEng News  Aug 30  Comment 
A team led by researchers from the Cleveland Clinic's Neurological Institute reports that a promising drug slowed brain shrinkage in progressive multiple sclerosis (MS) by nearly half. Limited therapies are currently available for this disabling...
MedPage Today  Aug 23  Comment 
(MedPage Today) -- Finding may open new research targets
GenEng News  Aug 22  Comment 
Scientists at the Cleveland Clinic report the discovery of a new subtype of multiple sclerosis (MS) that they say will provide a better understanding of the individualized nature of the disease. MS has long been characterized as a disease of...
FierceBiotech  Aug 9  Comment 
Republican Congressman Chris Collins has been charged with securities fraud. The case relates to a failed multiple sclerosis trial that precipitated a 92% drop in the stock price of Australian biotech Innate Immunotherapeutics.
The Economic Times  Aug 6  Comment 
The drug offers patients diagnosed with multiple sclerosis the efficacy and convenience of once-a-day oral treatment, Sanofi Genzyme said in a statement.




There is currently no text in this page, you can search for this page title in other pages or edit this page.
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki